Download PDF

1. Company Snapshot

1.a. Company Description

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform.It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression.The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders.


In addition, it focuses on developing GalNAc-conjugated AIMers to treat hepatic indications comprising Alpha-1 antitrypsin deficiency (AATD); and two preclinical programs, such as Usher syndrome type 2A (USH2A) and retinitis pigmentosa due to a P23H mutation in the RHO gene (RhoP23H) for the treatment of retinal diseases.It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, University of Massachusetts, Western Washington University, Grenoble Institute of Neurosciences, IRBM S.p.A, University of Louisville, and University College London.The company was incorporated in 2012 and is based in Singapore.

Show Full description

1.b. Last Insights on WVE

Negative drivers behind Wave Life Sciences' recent performance include the company's high research and development expenses, which increased by 25% year-over-year in Q4 2024. Additionally, the company's cash burn rate remains a concern, with a cash burn of $63 million in Q4 2024. Furthermore, the company's pipeline progress has been slow, with only one product candidate, WVE-N531, showing positive results in the FORWARD-53 study. The company's reliance on a single product candidate also raises concerns about its long-term viability.

1.c. Company Highlights

2. Wave Life Sciences' Q4 2025 Earnings: A Deeper Dive

The company's revenue for the fourth quarter was $17.2 million, a significant decline from $83.7 million in the prior year quarter. For the full year 2025, revenue was $42.7 million, down from $108.3 million in the prior year. The decrease was primarily due to revenue recognized upon the termination of the Takeda collaboration in October 2024. The actual EPS for the quarter came in at -$0.32, slightly missing estimates of -$0.3. Wave Life Sciences ended the year with $602.1 million in cash and cash equivalents, which is expected to be sufficient to fund operations into the third quarter of 2028.

Publication Date: Mar -01

📋 Highlights
  • Revenue Decline:: Q4 2025 revenue was $17.2 million vs. $83.7 million in Q4 2024; full-year 2025 revenue was $42.7 million vs. $108.3 million in 2024, primarily due to the terminated Takeda collaboration.
  • WVE-007 Obesity Data:: Single-dose 240mg/400mg cohorts in INLIGHT trial showed fat loss similar to semaglutide without muscle loss; 6-month (240mg) and 3-month (400mg) follow-up data expected later Q1 2026.
  • RNA Editing Pipeline:: WVE-006 (AATD) and WVE-008 (PNPLA3) advanced, with FDA feedback on AATD accelerated approval pathway anticipated by mid-2026.
  • Cash Runway:: $602.1 million in cash and equivalents, funding operations into Q3 2028, despite 2025 revenue decline.
  • Competitive Differentiation:: WVE-007’s once-to-twice-yearly dosing and lean mass preservation positioned as a differentiated obesity therapy vs. GLP-1s, with preclinical data showing sustained activin E reduction.

Operational Highlights

Wave Life Sciences made significant progress in its clinical programs, particularly with WVE-007 for obesity and WVE-006 for AATD. The company is on track to announce six-month follow-up data from the 240-milligram single-dose cohort and three-month follow-up data from the 400-milligram single-dose cohort in the INLIGHT study later this quarter. As Dr. Paul Bolno mentioned, "We're excited to build on our positive momentum and are energized now more than ever to unlock the full potential of our RNA medicines pipeline to transform human health."

Pipeline Advancements

The company's pipeline is progressing well, with WVE-007 showing promising results in obesity. The INLIGHT study demonstrated that a single dose of WVE-007 can shift body composition towards less visceral and total fat while preserving muscle. The upcoming data releases will be crucial in determining the efficacy of WVE-007. Analysts estimate revenue growth of 54.8% next year, indicating a strong potential for the company's pipeline assets.

Valuation Metrics

Wave Life Sciences' current valuation metrics indicate a high P/S Ratio of 60.56, suggesting that the market is pricing in significant growth expectations. The company's P/E Ratio is -12.28, and the EV/EBITDA is -9.87, indicating that the market is factoring in substantial losses. The ROE is -85.7%, and the Net Debt / EBITDA is 2.88, highlighting the company's current financial challenges.

3. NewsRoom

Card image cap

FDA reversals leave investors worrying about the fates of other experimental drugs

Mar -06

Source: cnbc.com

Card image cap

Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference

Mar -05

Source: globenewswire.com

Card image cap

Wave Life Sciences Ltd. (WVE) Q4 2025 Earnings Call Transcript

Feb -26

Source: seekingalpha.com

Card image cap

Wave Life Sciences (WVE) Reports Q4 Loss, Tops Revenue Estimates

Feb -26

Source: zacks.com

Card image cap

Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb -26

Source: globenewswire.com

Card image cap

Wave Life Sciences to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb -23

Source: globenewswire.com

Card image cap

Wave Life Sciences Fourth Quarter and Full Year 2025 Financial Results Scheduled for February 26, 2026

Feb -19

Source: globenewswire.com

Card image cap

Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development

Feb -19

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (12.05%)

6. Segments

Stereopure Oligonucleotides

Expected Growth: 12.05%

Wave Life Sciences' Stereopure Oligonucleotides growth is driven by increasing adoption in precision medicine, rising demand for targeted therapies, and advancements in genetic research. The company's proprietary chemistry platform enables high-quality oligonucleotides, fueling growth in the RNA therapeutics market.

7. Detailed Products

PRISM

A proprietary oligonucleotide platform designed to discover and develop novel stereopure oligonucleotides that can be used to treat a wide range of genetic diseases.

Stereopure oligonucleotides

A novel class of stereopure oligonucleotides that can be used to treat genetic diseases by selectively targeting specific RNA sequences.

PNAs (Peptide Nucleic Acids)

A novel class of molecules that can be used to target specific RNA sequences and modulate gene expression.

LNA (Locked Nucleic Acid) antisense oligonucleotides

A class of antisense oligonucleotides that can be used to target specific RNA sequences and modulate gene expression.

8. Wave Life Sciences Ltd.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Wave Life Sciences Ltd. has a moderate threat of substitutes due to the availability of alternative treatments and therapies for genetic disorders.

Bargaining Power Of Customers

Wave Life Sciences Ltd. has a low bargaining power of customers due to the lack of negotiating power among patients and healthcare providers.

Bargaining Power Of Suppliers

Wave Life Sciences Ltd. has a moderate bargaining power of suppliers due to the availability of multiple suppliers for raw materials and equipment.

Threat Of New Entrants

Wave Life Sciences Ltd. has a high threat of new entrants due to the growing interest in genetic research and development, making it easier for new companies to enter the market.

Intensity Of Rivalry

Wave Life Sciences Ltd. operates in a highly competitive industry with many established players, leading to a high intensity of rivalry.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 40.34%
Debt Cost 3.95%
Equity Weight 59.66%
Equity Cost -1.00%
WACC 1.00%
Leverage 67.61%

11. Quality Control: Wave Life Sciences Ltd. passed 2 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Halozyme Therapeutics

A-Score: 6.0/10

Value: 4.0

Growth: 9.1

Quality: 8.0

Yield: 0.0

Momentum: 9.0

Volatility: 6.0

1-Year Total Return ->

View Full Report
Stock-Card
Exelixis

A-Score: 5.9/10

Value: 4.1

Growth: 8.0

Quality: 9.4

Yield: 0.0

Momentum: 8.5

Volatility: 5.3

1-Year Total Return ->

View Full Report
Stock-Card
Incyte

A-Score: 5.7/10

Value: 3.8

Growth: 5.4

Quality: 9.1

Yield: 0.0

Momentum: 9.0

Volatility: 7.0

1-Year Total Return ->

View Full Report
Stock-Card
HUTCHMED

A-Score: 5.5/10

Value: 6.7

Growth: 7.6

Quality: 7.1

Yield: 0.0

Momentum: 4.0

Volatility: 7.7

1-Year Total Return ->

View Full Report
Stock-Card
Rovi

A-Score: 4.8/10

Value: 1.8

Growth: 7.7

Quality: 8.1

Yield: 2.5

Momentum: 3.0

Volatility: 6.0

1-Year Total Return ->

View Full Report
Stock-Card
Wave Life Sciences

A-Score: 3.8/10

Value: 6.0

Growth: 5.4

Quality: 4.6

Yield: 0.0

Momentum: 5.0

Volatility: 2.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

14.08$

Current Price

14.08$

Potential

0.00%

Expected Cash-Flows